JP2019533715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533715A5 JP2019533715A5 JP2019525021A JP2019525021A JP2019533715A5 JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5 JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- ldl
- pcsk9
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023019926A JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421685P | 2016-11-14 | 2016-11-14 | |
| US62/421,685 | 2016-11-14 | ||
| US201762471874P | 2017-03-15 | 2017-03-15 | |
| US62/471,874 | 2017-03-15 | ||
| US201762515117P | 2017-06-05 | 2017-06-05 | |
| US62/515,117 | 2017-06-05 | ||
| US201762581244P | 2017-11-03 | 2017-11-03 | |
| US62/581,244 | 2017-11-03 | ||
| US201762584600P | 2017-11-10 | 2017-11-10 | |
| US62/584,600 | 2017-11-10 | ||
| PCT/US2017/061346 WO2018089912A2 (en) | 2016-11-14 | 2017-11-13 | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Division JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533715A JP2019533715A (ja) | 2019-11-21 |
| JP2019533715A5 true JP2019533715A5 (https=) | 2020-12-24 |
Family
ID=60484496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019525021A Pending JP2019533715A (ja) | 2016-11-14 | 2017-11-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200368350A1 (https=) |
| EP (1) | EP3538149A2 (https=) |
| JP (3) | JP2019533715A (https=) |
| KR (2) | KR20190085963A (https=) |
| CN (1) | CN110234350A (https=) |
| AU (2) | AU2017356219A1 (https=) |
| BR (1) | BR112019009726A2 (https=) |
| CA (1) | CA3043700A1 (https=) |
| CL (2) | CL2019001304A1 (https=) |
| CO (1) | CO2019004814A2 (https=) |
| IL (2) | IL326501A (https=) |
| JO (1) | JOP20190112A1 (https=) |
| MA (1) | MA46758A (https=) |
| MX (3) | MX2019005627A (https=) |
| TN (1) | TN2019000156A1 (https=) |
| WO (1) | WO2018089912A2 (https=) |
| ZA (1) | ZA201902975B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| US20210290580A1 (en) * | 2018-07-31 | 2021-09-23 | Wen Tan | New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US12608440B2 (en) | 2019-07-19 | 2026-04-21 | Ebay Inc. | Sample delta monitoring |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2874149T3 (es) | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US9493774B2 (en) * | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| NZ597504A (en) | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| KR20130118925A (ko) | 2010-12-22 | 2013-10-30 | 제넨테크, 인크. | 항-pcsk9 항체 및 사용 방법 |
| AU2012214251A1 (en) | 2011-02-11 | 2013-09-12 | Novartis Ag | PCSK9 antagonists |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| AU2015231713B2 (en) * | 2014-03-17 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Methods for reducing cardiovascular risk |
| CA2973116C (en) * | 2015-01-09 | 2023-08-15 | Global Genomics Group, LLC | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease |
-
2017
- 2017-06-16 JO JOP/2019/0112A patent/JOP20190112A1/ar unknown
- 2017-11-13 TN TNP/2019/000156A patent/TN2019000156A1/en unknown
- 2017-11-13 JP JP2019525021A patent/JP2019533715A/ja active Pending
- 2017-11-13 MX MX2019005627A patent/MX2019005627A/es unknown
- 2017-11-13 AU AU2017356219A patent/AU2017356219A1/en not_active Abandoned
- 2017-11-13 US US16/348,653 patent/US20200368350A1/en active Pending
- 2017-11-13 MA MA046758A patent/MA46758A/fr unknown
- 2017-11-13 KR KR1020197016872A patent/KR20190085963A/ko not_active Ceased
- 2017-11-13 IL IL326501A patent/IL326501A/en unknown
- 2017-11-13 EP EP17805364.1A patent/EP3538149A2/en active Pending
- 2017-11-13 KR KR1020247018411A patent/KR20240096648A/ko active Pending
- 2017-11-13 BR BR112019009726-0A patent/BR112019009726A2/pt unknown
- 2017-11-13 WO PCT/US2017/061346 patent/WO2018089912A2/en not_active Ceased
- 2017-11-13 CN CN201780083280.9A patent/CN110234350A/zh active Pending
- 2017-11-13 CA CA3043700A patent/CA3043700A1/en active Pending
-
2019
- 2019-05-12 IL IL266579A patent/IL266579A/en unknown
- 2019-05-13 CO CONC2019/0004814A patent/CO2019004814A2/es unknown
- 2019-05-13 CL CL2019001304A patent/CL2019001304A1/es unknown
- 2019-05-13 ZA ZA2019/02975A patent/ZA201902975B/en unknown
- 2019-05-14 MX MX2024000805A patent/MX2024000805A/es unknown
- 2019-05-14 MX MX2025002106A patent/MX2025002106A/es unknown
-
2020
- 2020-11-18 CL CL2020002993A patent/CL2020002993A1/es unknown
-
2023
- 2023-02-13 JP JP2023019926A patent/JP2023071715A/ja active Pending
-
2024
- 2024-12-06 AU AU2024278180A patent/AU2024278180A1/en active Pending
-
2025
- 2025-03-04 JP JP2025033900A patent/JP2025102770A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533715A5 (https=) | ||
| Garay et al. | Therapeutic perspectives on uricases for gout | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2017528427A5 (https=) | ||
| JP2017506626A5 (https=) | ||
| JP2015518897A5 (https=) | ||
| Simon et al. | Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL study | |
| Szadkowska et al. | Statin therapy in the elderly: a review | |
| KR20160043117A (ko) | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 | |
| Bertrand et al. | Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine | |
| A. Mangiafico et al. | Medical treatment of critical limb ischemia: current state and future directions | |
| Constance et al. | Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects≥ 65 years | |
| US9713608B2 (en) | Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| Teixeira | Scientific basis of the homeopathic healing principle in modern pharmacology | |
| Bauters et al. | Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact | |
| Amuchastegui et al. | Disulfiram--alcohol reaction mimicking an acute coronary syndrome. | |
| Polska | Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients | |
| WO2008121461A3 (en) | Vaccine for activating helper function of cd8+ tcells | |
| JPWO2006104086A1 (ja) | 血栓症治療剤 | |
| Hadjibabaie et al. | Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients | |
| Cinquegrani et al. | MRSA bacteremia and new-onset aortic and mitral regurgitation: a pernicious and tricky association |